The ICR was established in June 2016 through an innovative partnership between Colorado State University – Pueblo, the state of Colorado, and Pueblo County.
With initial funding support from Pueblo County and the state of Colorado, the ICR is the nation’s first multi-disciplinary cannabis research center at a regional, comprehensive institution. The primary function of the Institute is the generation of knowledge that contributes to science, medicine, and society through investigation of the benefits and risks associated with cannabis. Research findings are used to translate discoveries into innovative applications that improve lives.
For more information about ICR, visit csupueblo.edu/institute-of-cannabis-research.
The ICR was established in June 2016 through an innovative partnership between Colorado State University – Pueblo, the state of Colorado, and Pueblo County.
With initial funding support from Pueblo County and the state of Colorado, the ICR is the nation’s first multi-disciplinary cannabis research center at a regional, comprehensive institution. The primary function of the Institute is the generation of knowledge that contributes to science, medicine, and society through investigation of the benefits and risks associated with cannabis. Research findings are used to translate discoveries into innovative applications that improve lives.
For more information about ICR, visit csupueblo.edu/institute-of-cannabis-research.
MECHOULAM
LECTURE
Linda A Parker, PhD is the author of Cannabinoids and the Brain (MIT Press, 2017) and, along with Raphael Mechoulam and Erin Rock, CBD: What the Science Says (MIT Press, 2022).
She is currently University Professor Emeritus at the University of Guelph, Ontario, Canada, where she held a Tier 1 Canada Research Chair (until July 1, 2020) in Behavioral Neuroscience.
She has over 200 publication most recently focused upon understanding the functioning of the endocannabinoid system and how plant derived cannabinoids act in the brain.
She is past-President of the Canadian Consortium for the Investigation of Cannabinoids, having served on its executive board since 2007. She was awarded the Lifetime Achievement Award from the International Cannabinoid Research Society (2017) and the Medal of Merit from the University of Guelph (2022) for her contributions toward understanding the role of the endocannabinoid system in the regulation of nausea.
![LindaParker4 RobO[1] (1).jpg](https://static.wixstatic.com/media/a07d2f_411e274ac0874b73a22121dc054ce309~mv2.jpg/v1/fill/w_564,h_375,al_c,q_80,usm_0.66_1.00_0.01,enc_auto/a07d2f_411e274ac0874b73a22121dc054ce309~mv2.jpg)
KEYNOTE
SPEAKER
Dr. Rachel Knox, MD, MBA is an endocannabinologist specializing in cannabinoid medicine, and is a thought leader and policy expert in cannabis and psychedelics health equity. She received her medical and business degrees from Tufts School of Medicine after completing her undergraduate studies at Duke, training in family and integrative medicine before pursuing additional study in the areas of functional medicine, cannabinology, and endocannabinology.
She is the creator, co-founder, and president of the Cannabis Health Equity Movement (CHEM)™, chairing the movement’s non-profit organizations: the Association for Cannabis Health Equity and Medicine (ACHEM) and CHEM Allyance. From CHEM to her work in cannabis and psychedelics policy and regulation, Dr. Rachel centers advocacy around the roles cannabis, psychedelics, and other earth resources can play in addressing the Minority Health Disparity Gap as applied to the CHEM Pillars of Health Equity™, a rubric she developed to drive competency around equity, measure access to wellbeing, and appraise the impact of social and economic effort in the pursuit of ensuring access to full health and wellbeing for all people.
Along with her family, Dr. Rachel founded Doctors Knox, Inc. and Pivital Holdings, the latter to develop transformative education and health solutions to improve well care access, promote health and data equity, and develop botanical and biotherapeutic product innovations targeting under-invested and overlooked physical and mental health issues in BIPOC and other historically excluded communities.
Dr. Rachel serves her home state of Oregon as the immediate past chair of the Oregon Cannabis Commission and long-term member of Portland's Cannabis Policy Oversight Team, Equity Chair of Oregon’s Psilocybin Advisory Board, and board member for NuProject. She also sits on several national boards including Cannabis Regulators of Color Coalition (CRCC), Doctors for Cannabis Regulation (DFCR), Minority Cannabis Business Association (MCBA), Council for Federal Cannabis Regulation, and US
Cannabis Council.
.png)
